Principia Biopharma Inc (NASDAQ:PRNB) insider David Goldstein sold 6,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $70.90, for a total value of $425,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Principia Biopharma stock opened at $64.66 on Friday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -76.07 and a beta of 1.39. The business has a 50-day moving average price of $58.49 and a 200-day moving average price of $41.83. Principia Biopharma Inc has a twelve month low of $25.35 and a twelve month high of $75.65.
Institutional investors have recently modified their holdings of the company. Great West Life Assurance Co. Can purchased a new position in shares of Principia Biopharma during the fourth quarter valued at about $83,000. Bank of Montreal Can lifted its holdings in shares of Principia Biopharma by 88.6% in the 4th quarter. Bank of Montreal Can now owns 2,320 shares of the company’s stock valued at $127,000 after acquiring an additional 1,090 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Principia Biopharma in the 4th quarter valued at about $134,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Principia Biopharma in the 4th quarter valued at about $140,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Principia Biopharma by 393.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,674 shares of the company’s stock valued at $201,000 after acquiring an additional 2,930 shares during the last quarter. Hedge funds and other institutional investors own 61.64% of the company’s stock.
PRNB has been the subject of a number of analyst reports. Wells Fargo & Co reiterated a “buy” rating and issued a $82.00 price target (up previously from $63.00) on shares of Principia Biopharma in a research note on Friday, February 7th. HC Wainwright increased their price target on Principia Biopharma from to and gave the stock a “buy” rating in a research note on Thursday, February 6th. ValuEngine lowered Principia Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, December 10th. Stifel Nicolaus reiterated a “buy” rating on shares of Principia Biopharma in a research note on Tuesday, December 31st. Finally, BidaskClub upgraded Principia Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $64.40.
About Principia Biopharma
Principia Biopharma Inc, a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura.
Featured Article: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.